Danish precision fermentation player 21st.Bio has submitted an EU regulatory application for its recombinant beta-lactoglobulin protein, calling for a “fast-track pathway” to approval.
Copenhagen-based 21st.Bio has filed a regulatory dossier seeking approval to sell a key precision-fermented milk protein in the EU.
The startup is eyeing the green light for BLG+ Essential, its recombinant beta-lactoglobulin protein, and is calling on the European Food Safety Authority (EFSA) to fast-track its authorisation process.
The EU regulator’s novel food process is notoriously slow and expensive, and has dissuaded many companies from commercialising in this region. Many European future food players have looked to other markets first, including 21st.Bio, which obtained clearance to sell its animal-free whey protein in the US two years ago.
The firm is calling for a speedier process for nature-identical proteins that are well-characterised and produced with host strains and technologies with a proven record of safe use. It argues that this will preserve the EU’s high safety standards while providing applicants with a clearer timetable.
“This is not a choice between safety and speed,” said 21st.Bio co-founder and CEO Thomas G Schmidt. “It is an opportunity to apply the best science to achieve both. Europe can protect consumers, offer healthy and nutritious food options to Europeans, and offer nutritional self-sufficiency, industrial production, skilled jobs and sustained technology leadership.”
A novel protein built on decades of research

Precision fermentation involves inserting a specific DNA sequence into microbes to instruct them to produce the desired molecules when fermented. 21st.Bio, founded by Schmidt and CSO Per Falholt in 2020, licenses part of its technology from biosolutions giant Novonesis (owned by Novo Holdings, the parent company of Ozempic maker Novo Nordisk).
In 2021, Novo Holdings invested €86M ($97M at the time) in 21st.Bio against an ownership share. The Novonesis licence gives 21st.Bio access to one of the world’s most advanced expression technologies, and strains that have been optimised for over 40 years.
The startup, which has labs in both Copenhagen and Davis, California, serves as an end-to-end partner helping bioindustrial companies scale up from molecular innovation to industrial production, and already sells many ingredients to manufacturers in the food and drink, sweet protein, collagen, biomaterials, agriculture, and biomining spaces.
Its focus on beta-lactoglobulin comes amid the ongoing whey supply crisis. Whey prices have hit all-time highs across the US and Europe. In fact, the cost of this dairy ingredient has increased fivefold over the last year. At the same time, global dairy output is struggling to keep up, and is projected to fall short by 31 million tonnes of milk equivalents by the end of the decade.
But the demand for protein is skyrocketing, which 21st.Bio ascribes to two forces: ageing populations and GLP-1 users, both of whom need more protein to maintain muscle mass and metabolic health. That has prompted manufacturers to look for more climate-friendly and -resilient alternatives to whey.
This is why 21st.Bio is targeting beta-lactoglobulin, the main whey protein in cow’s milk. The firm uses Aspergillus oryzae (also called koji mould), a microorganism used for centuries to ferment products like soy sauce, miso, sake and shochu, to produce the protein, with the precision fermentation process enabling a stable supply with a fraction of the climate footprint of conventional whey.
Europe needs domestic infrastructure to help fermentation startups scale up

Beta-lactoglobulin comprises 65% of dairy’s whey content, and is revered for its gelling, foaming and emulsification properties, enabling manufacturers to enhance the mouthfeel and texture of products. Scientists have suggested that, when it comes to muscle and metabolic health, this outperforms all other forms of whey and casein proteins in dairy.
The protein contains 45% more leucine than commercially available whey protein isolates, which is key for muscle synthesis. It’s tasteless, stable across a wide pH range, and heat-tolerant, while supporting fast absorption and high digestibility.
These properties make it suitable for a wide range of formulations, from plant-based and hybrid dairy products to clear protein drinks, pancakes, soups, and baked goods. BLG Essential+ can enhance these foods’ nutrition, texture, and stability, as well as offer consistent, scalable, and sustainable production.
21st.Bio licenses its precision fermentation tech to other innovators, enabling them to reach the market faster with robust safety checks. A peer-reviewed study last year described its strain lineage as the first mycotoxin-free Aspergillus oryzae lineage for industrial production of alternative and novel proteins.
The researchers documented the absence of known mycotoxin biosynthesis pathways, and noted that additional modifications inactivated the penicillin G cluster to ensure that the strain does not produce antibiotics or other unintended secondary metabolites.
21st.Bio is among a number of startups producing precision-fermented beta-lactoglobulin. Californian pioneer Perfect Day, Israel’s Remilk and Imagindairy, Dutch startup Vivici, and French firm Verley have all been cleared to sell their versions in the US. However, the EU is yet to approve these novel food ingredients.
“Europe has the science, the companies and the industrial heritage in precision fermentation to lead the wave of healthy and nutritious food production,” argued Schmidt, whose firm is also working on alpha-lactalbumin (another whey protein).
“What Europe still needs is a home market that allows industrially proven technology to move from laboratories into fermentation factories built in Europe. A predictable, science-based route to market can strengthen food resilience, attract industrial investment and ensure that European innovation is commercialised in Europe.”
